Protocol Ledger

NCT06646276 · Phase III · RECRUITING

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line

Interventional Phase III clinical trial protocol NCT06646276 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-25 Enrollment: 530 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06646276
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)530 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06646276
Protocol FieldVerified Registry Value
NCT IdentifierNCT06646276
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment530 participants (ESTIMATED)
Registered Start Date2025-02-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06646276
Hospital Research SiteLocationSite Profile
Florida Cancer Specialists (Fort Myers)Fort Myers, FLOpen Hospital Dossier ->
Florida Cancer Specialists (Saint Petersburg)Saint Petersburg, FLOpen Hospital Dossier ->
Duke University Medical CenterDurham, NCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI